These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8497347)

  • 41. [Metabolic risks of oral contraception].
    Monier L
    Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Contraception for the diabetic woman].
    Arlot S; Mesmacque A; Lalau JD; Quichaud J
    Fertil Contracept Sex; 1988 Nov; 16(11):921-6. PubMed ID: 12282829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current issues in contraception].
    Audebert AJ
    Contracept Fertil Sex (Paris); 1985 Feb; 13(2):467-73. PubMed ID: 12339971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Progress in combined oral contraception: gestodene, a third generation progestogen].
    Belaïsch J
    Rev Fr Gynecol Obstet; 1989 May; 84(5):455-9. PubMed ID: 2740714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    Odlind V; Milsom I; Persson I; Victor A
    Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The characteristics of triphasic estrogen-progesterone contraceptives and their theoretical indications].
    Senèze J
    Rev Fr Gynecol Obstet; 1990 May; 85(5):301-5. PubMed ID: 2374864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
    Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
    Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Classification and comparison of oral contraceptives containing new generation progestogens.
    Newton JR
    Hum Reprod Update; 1995 May; 1(3):231-63. PubMed ID: 9187941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical analysis of a new triphasic estroprogestational combination with gestodene].
    Mühe B; Vital MH
    Rev Fr Gynecol Obstet; 1988 Apr; 83(4):283-5. PubMed ID: 3393800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The androgenicity of progestins.
    Darney PD
    Am J Med; 1995 Jan; 98(1A):104S-110S. PubMed ID: 7825629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.
    Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL
    Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The androgenicity of progestational agents.
    Lobo RA
    Int J Fertil; 1988; 33 Suppl():6-12. PubMed ID: 2908040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism.
    Stanczyk FZ
    Contraception; 1997 May; 55(5):273-82. PubMed ID: 9220223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Marvelon--an OC with a new progestagen.
    Drug Ther Bull; 1984 Sep; 22(18):69-70. PubMed ID: 6236963
    [No Abstract]   [Full Text] [Related]  

  • 59. [New progestins in oral hormonal contraceptives].
    Runnebaum B; Rabe T
    Arch Gynecol Obstet; 1989; 245(1-4):1000-5. PubMed ID: 2679410
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Biological status of adolescent girls using estrogen-progestins].
    Macaigne M; Amouyel P; Isorez-Decocq D; Sinn MC; Zylbergerg G
    Contracept Fertil Sex; 1995 Sep; 23(9):541-4. PubMed ID: 7496427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.